Detalhe da pesquisa
1.
Hypocalcaemia after treatment with [177Lu-DOTA 0,Tyr3]octreotate.
Eur J Nucl Med Mol Imaging
; 40(12): 1843-52, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23877632
2.
Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy.
Neuroendocrinology
; 97(1): 74-85, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-22237390
3.
Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate.
J Nucl Med
; 56(11): 1647-53, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26272813
4.
Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3]octreotate.
J Nucl Med
; 54(10): 1689-96, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24084705
5.
Tumor response assessment to treatment with [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors: differential response of bone versus soft-tissue lesions.
J Nucl Med
; 53(9): 1359-66, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22782312
6.
Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.
Best Pract Res Clin Gastroenterol
; 26(6): 867-81, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23582925